veski news

Each year in Australia over 1000 people are diagnosed with acute myeloid leukaemia (AML), an aggressive blood cancer. Less than one third of AML patients survive 5 years beyond diagnosis. Researchers from Monash University have discovered a key reason why this disease is so difficult to treat and therefore cure.

Monash University materials scientists, led by veski innovation fellow Professor Christopher McNeill, have helped uncover an important breakthrough in fundamental physics that further paves the way for the development of next-generation flexible, wearable devices powered by ‘spintronics’.

Associate Professor Natalie Hannan, veski inspiring women fellow and 2018 veski inspiring women STEM sidebyside program participant, was announced as Associate Dean, Diversity and Inclusion, in the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.

veski delivered its first veski conversation for the 2019/20 financial year on 9 July on The Future of Business, Government and Society: Together we will Imagine, Enable and Build the Future. The evening conversation was attended by an audience of SMEs, government and industry practitioners.

Letter to the editor By Julia Page, MD & chief executive of veski

Congratulations to inaugural veski inspiring women fellow Associate Professor Natalie Hannan, Department of Obstetrics and Gynaecology, Melbourne Medical School, Mercy Hospital for Women, on being awarded the 2019 Melbourne Medical School Strategic Grants for Outstanding Women, as well as the International Federation of Placenta Associations, Andrèe Gruslin Award for 2019.

Prostate cancer is one of Australia’s biggest killers: 1 in 7 Australian men will be diagnosed with the disease by the age of 85.

It’s no wonder our scientists, at research labs in Melbourne, are working hard to arrest these figures.

CSIRO scientists are developing a way to improve the body’s defences against prostate cancer (and a host of other cancers) and their research is focussed on a specific protein called E6AP.

It turns out there are certain types of proteins in our bodies with the potential to destroy other proteins that protect us from cancer developing.